Search

Search Constraints

You searched for: Author/Creator Dhermain, Frederic

Search Results

1. RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. (5th November 2018)

2. NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. (12th November 2021)

3. Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials. (March 2022)

4. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. Issue 10 (14th February 2022)

5. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Issue 5 (18th December 2013)

7. Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. (June 2019)

8. An Unusual Case of Constitutional Mismatch Repair Deficiency Syndrome With Anaplastic Ganglioglioma, Colonic Adenocarcinoma, Osteosarcoma, Acute Myeloid Leukemia, and Signs of Neurofibromatosis Type 1: Case Report. Issue 1 (4th April 2015)

9. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Issue 6 (June 2021)

10. NCOG-19. BEVACIZUMAB IN REAL LIFE PATIENTS WITH RECURRENT GLIOBLASTOMA: BENEFIT OR FUTILITY?. (9th November 2020)